Aldeyra Therapeutics to Participate in the Jefferies and A.G.P./Alliance Global Partners Virtual Investor Conferences
November 13 2020 - 7:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced that the company’s senior management will participate in
the following virtual investor conferences:
- Jefferies Virtual London Healthcare Conference: Aldeyra
President and CEO Todd C. Brady, M.D., Ph.D., is scheduled to
participate in a fireside chat at 1:10 p.m. ET on Wednesday,
November 18, 2020. The fireside chat will be broadcast live and
archived for 90 days on the company’s website at
https://ir.aldeyra.com/on the “Events & Presentations” page. In
addition, company executives are scheduled to host virtual
one-on-one meetings with institutional investors.
- A.G.P./Alliance Global Partners Virtual Healthcare
Symposium: Aldeyra executives are scheduled to host virtual
one-on-one meetings with institutional investors on November 19,
2020.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company
focused on the development of novel therapies with the potential to
improve the lives of patients with immune-mediated diseases. Two of
the company’s lead compounds, reproxalap and ADX-629, target
reactive aldehyde species (RASP), which are elevated in ocular and
systemic inflammatory disease, leading to elevated levels of
cytokine release via activation of a broad array of inflammatory
factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Reproxalap is being evaluated in Phase 3 clinical trials in
patients with dry eye disease and allergic conjunctivitis. The
company’s clinical pipeline also includes ADX-2191, a dihydrofolate
reductase inhibitor in Phase 3 testing for proliferative
vitreoretinopathy, and ADX-1612, a chaperome inhibitor in
development for COVID-19 and ovarian cancer. For more information,
visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook,
and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201113005085/en/
Corporate Contact: David McMullin Aldeyra Therapeutics,
Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2024 to May 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From May 2023 to May 2024